July 30, 2019
The Institute of Interventional Oncology (IDOI México) is a multidisciplinary oncology team that treats Diffuse Intrinsic Pontine Glioma (DIPG) and other “Go home, make memories” types of cancer with novel and multimodal approaches to the disease, improving the patient’s survival and quality of life.
IDOI México’s unrestrained model of treatment is individualized to the patient’s particular needs, which is exactly the reason IDOI was born in the first place.
DIPG is a highly aggressive tumor in the pons with a historic poor prognostic that affects mostly children, from around the world.
The last decade studies focused their efforts on ideal monotherapies to attack diverse pathways with different levels of success but no clear cure so far. Systemic chemotherapy results mostly ineffective: radiotherapy and steroids have proved themselves merely palliative while bringing their own set of adverse effects.
While standard protocols will hopefully bring an adequate treatment or final cure for DIPG in the future, TODAY, individualized and compassionate use programs around the world are the only chance for any improvement to most of the currently afflicted patients.
According to Hoffman et al., 2018, the largest DIPG case study done to date, the “progression of the disease” by RANO criteria was given 6 months after diagnosis with a rapid deterioration. The overall survival of the DIPG patient (50% deceased) is 11 months after diagnosis. Then, at one year, 2 years and 5 years, only 42.3%, 9.6% and 2.2% of patients will still be alive.
The overall survival of the DIPG patient treated by IDOI México is over 20 months, most regaining quality of life coming from various degrees of the progression of the disease.
IDOI México has obtained international recognition thanks to the positive responses in quality of life and improved survival of over 60 DIPG cases from around the world using Super-Selective Intra-Arterial & Intrathecal Chemotherapy (SSIAITC, a minimally invasive procedure).